Get Ready for ONWARD:
OPZELURA Learning Sessions

Join Us for an Educational Webinar About Nonsegmental Vitiligo

Learn more about OPZELURA™ (ruxolitinib) as a potential treatment option for nonsegmental vitiligo in people aged 12 years and older.

ONWARD: Opzelura Learning Sessions are webinars designed to help people living with nonsegmental vitiligo and their loved ones learn about the first FDA-approved medication for this condition.

Ask questions about OPZELURA and participate along with others who are living with nonsegmental vitiligo. Learn more about nonsegmental vitiligo and find out about support options. When you register, you’ll also receive a packet of resources to help you become more informed.

The speaker will not provide medical advice. Your healthcare provider is the best source of information about your health.

Upcoming Webinars

Click arrows to see additional webinar dates

During the educational webinar you will be able to:

  • Get tips for communicating with your healthcare provider and tracking your treatment
  • Learn about OPZELURA, an FDA-approved medication option for nonsegmental vitiligo in adults and children aged 12 years and older
  • Hear from a dermatology specialist and ask questions
  • Once the webinar has ended, attend a breakout room to connect with other people who are living with nonsegmental vitiligo and see what types of questions they may have about their condition
  • Find out what kinds of support are available for people living with nonsegmental vitiligo
  • The speaker will not provide medical advice; your healthcare provider is the best source of information about your health

Frequently Asked Questions

    How does the webinar work?

    We will email you a link to the webinar once you register, and we’ll send another link in a reminder email.

    Be sure to check your spam folder if you have not received the link.

    Fifteen minutes before the webinar is scheduled to start, click the link and the webinar site will open. No plug-ins or downloads are needed.

    You can click the link any time before the webinar to visit the website to add the event to your calendar, see a brief summary of the webinar, or read the FAQs.

    If you have questions or need assistance, call 919-256-2480.

    Can this webinar run on my device?

    You can access the webinar from a desktop computer or a mobile device (smartphones, tablets, laptops, etc) The webinar is compatible with most internet browsers as well, including Chrome, Firefox, Safari, and Edge.

    Check your device compatibility

    Will I be able to attend anonymously?

    Neither the speaker nor the attendees will see your name or your image. You may type your questions anonymously into the Q&A chat feature. Your computer’s camera will not be used during the webinar.

    Who can attend the webinar?

    ONWARD: Opzelura Learning Sessions are open to anyone living with nonsegmental vitiligo who would like to learn more about this prescription cream option. Family and friends who would like to learn more about nonsegmental vitiligo, OPZELURA for nonsegmental vitiligo, or how to support a loved one living with nonsegmental vitiligo are also welcome to register.

    Who is presenting the webinar?

    All presenters are healthcare professionals contracted and paid by Incyte. These presenters will not provide medical advice. Your healthcare professional is the best source of information about your health.

    Will I receive any resources?

    Yes, prior to the event you will receive a package of materials in the mail to the address you provided during registration. It will include a workbook of the slides being presented with a section for capturing notes, along with OPZELURA-specific materials.

    INDICATION AND USAGE

    OPZELURA is a prescription medicine used on the skin (topical) for the treatment of a type of vitiligo called nonsegmental vitiligo in adults and children 12 years of age and older.

    The use of OPZELURA along with therapeutic biologics, other JAK inhibitors, or strong immunosuppressants such as azathioprine or cyclosporine is not recommended.

    It is not known if OPZELURA is safe and effective in children less than 12 years of age with nonsegmental vitiligo.

    IMPORTANT SAFETY INFORMATION

    OPZELURA is for use on the skin only. Do not use OPZELURA in your eyes, mouth, or vagina.

    OPZELURA may cause serious side effects, including:

    Serious Infections: OPZELURA contains ruxolitinib. Ruxolitinib belongs to a class of medicines called Janus kinase (JAK) inhibitors. JAK inhibitors are medicines that affect your immune system. JAK inhibitors can lower the ability of your immune system to fight infections. Some people have had serious infections while taking JAK inhibitors by mouth, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have been hospitalized or died from these infections. Some people have had serious infections of their lungs while taking OPZELURA. Your healthcare provider should watch you closely for signs and symptoms of TB during treatment with OPZELURA.

    OPZELURA should not be used in people with an active, serious infection, including localized infections. You should not start using OPZELURA if you have any kind of infection unless your healthcare provider tells you it is okay. You may be at a higher risk of developing shingles (herpes zoster) while using OPZELURA.

    Increased risk of death due to any reason (all causes): Increased risk of death has happened in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and are taking a medicine in the class of medicines called JAK inhibitors by mouth.

    Cancer and immune system problems: OPZELURA may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers have happened in people taking a medicine in the class of medicines called JAK inhibitors by mouth. People taking JAK inhibitors by mouth have a higher risk of certain cancers including lymphoma and lung cancer, especially if they are a current or past smoker. Some people have had skin cancers while using OPZELURA. Your healthcare provider will regularly check your skin during your treatment with OPZELURA. Limit the amount of time you spend in the sunlight. Wear protective clothing when you are in the sun and use a broad-spectrum sunscreen.

    Increased risk of major cardiovascular events: Increased risk of major cardiovascular events such as heart attack, stroke, or death have happened in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and taking a medicine in the class of medicines called JAK inhibitors by mouth, especially in current or past smokers.

    Blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) can happen in some people taking OPZELURA. This may be life-threatening. Blood clots in the vein of the legs (deep vein thrombosis, DVT) and lungs (pulmonary embolism, PE) have happened more often in people who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking a medicine in the class of medicines called JAK inhibitors by mouth.

    Low blood cell counts: OPZELURA may cause low platelet counts (thrombocytopenia), low red blood cell counts (anemia), and low white blood cell counts (neutropenia). If needed, your healthcare provider will do a blood test to check your blood cell counts during your treatment with OPZELURA and may stop your treatment if signs or symptoms of low blood cell counts happen.

    Cholesterol increases: Cholesterol increase has happened in people when ruxolitinib is taken by mouth. Tell your healthcare provider if you have high cholesterol or triglycerides.

    Before starting OPZELURA, tell your healthcare provider if you:

    • have an infection, are being treated for one, or have had an infection that does not go away or keeps coming back
    • have diabetes, chronic lung disease, HIV, or a weak immune system
    • have TB or have been in close contact with someone with TB
    • have had shingles (herpes zoster)
    • have or have had hepatitis B or C
    • live, have lived in, or have traveled to certain parts of the country (such as the Ohio and Mississippi River valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections. These infections may happen or become more severe if you use OPZELURA. Ask your healthcare provider if you do not know if you have lived in an area where these infections are common.
    • think you have an infection or have symptoms of an infection such as: fever, sweating, or chills, muscle aches, cough or shortness of breath, blood in your phlegm, weight loss, warm, red, or painful skin or sores on your body, diarrhea or stomach pain, burning when you urinate or urinating more often than usual, feeling very tired.
    • have ever had any type of cancer, or are a current or past smoker
    • have had a heart attack, other heart problems, or a stroke
    • have had blood clots in the veins of your legs or lungs in the past
    • have high cholesterol or triglycerides
    • have or have had low white or red blood cell counts
    • are pregnant or plan to become pregnant. It is not known if OPZELURA will harm your unborn baby. There is a pregnancy exposure registry for individuals who use OPZELURA during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. If you become exposed to OPZELURA during pregnancy, you and your healthcare provider should report exposure to Incyte Corporation at 1-855-463-3463.
    • are breastfeeding or plan to breastfeed. It is not known if OPZELURA passes into your breast milk. Do not breastfeed during treatment with OPZELURA and for about 4 weeks after the last dose.

    After starting OPZELURA:

    • Call your healthcare provider right away if you have any symptoms of an infection. OPZELURA can make you more likely to get infections or make worse any infections that you have.
    • Get emergency help right away if you have any symptoms of a heart attack or stroke while using OPZELURA, including:
      • discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back
      • severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
      • pain or discomfort in your arms, back, neck, jaw, or stomach
      • shortness of breath with or without chest discomfort
      • breaking out in a cold sweat
      • nausea or vomiting
      • feeling lightheaded
      • weakness in one part or on one side of your body
      • slurred speech
    • Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with OPZELURA, including: swelling, pain, or tenderness in one or both legs, sudden, unexplained chest or upper back pain, or shortness of breath or difficulty breathing.
    • Tell your healthcare provider right away if you develop or have worsening of any symptoms of low blood cell counts, such as: unusual bleeding, bruising, tiredness, shortness of breath, or fever.

    Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

    The most common side effects of OPZELURA in people treated for nonsegmental vitiligo include: acne at the application site, itching at the application site, common cold (nasopharyngitis), headache, urinary tract infection, redness at the application site, and fever.

    These are not all of the possible side effects of OPZELURA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Incyte Corporation at 1-855-463-3463.

    Please see the Full Prescribing Information, including Boxed Warning, and Medication Guide for OPZELURA.

    This website is intended for US residents only.

    OPZELURA is a trademark of Incyte. Incyte and the Incyte logo are registered trademarks of Incyte.

    © 2023, Incyte Corporation. MAT-OPZ-00922 09/22